期刊文献+

塞瑞替尼有关物质的合成

Synthesis of the Related Substances of Ceritinib
原文传递
导出
摘要 根据塞瑞替尼(1)结构及合成工艺,制备了8个有关物质:5-氯-2-异丙氧基-N-[2-(异丙基磺酰基)苯基]-4-嘧啶胺(有关物质A)、5-氯-4-[[2-(异丙基磺酰基)苯基]氨基]-2-嘧啶醇(有关物质B)、5-氯-N^(2)-[2-异丙氧基-5-甲基-4-(哌啶-4-基)苯基]-N^(4)-[2-(异丙基亚硫酰基)苯基]-2,4-嘧啶二胺(有关物质C)、5-氯-N^(2)-[2-异丙氧基-5-甲基-4-(哌啶-4-基)苯基]-N^(4)-[2-(丙基磺酰基)苯基]-2,4-嘧啶二胺(有关物质D)、5-氯-N^(4)-[2-异丙氧基-5-甲基-4-(哌啶-4-基)苯基]-N^(2)-[2-(异丙基磺酰基)苯基]-2,4-嘧啶二胺(有关物质E)、2-[[5-氯-4-[[2-(异丙基磺酰基)苯基]-氨基]嘧啶-2-基]氨基]-4-甲基-5-(哌啶-4-基)苯酚(有关物质F)、4-[4-[4-[[5-氯-4-[[2-(异丙基磺酰基)苯基]-氨基]-嘧啶-2-基]氨基]-5-异丙氧基-2-甲基苯基]哌啶-1-基]戊-2-酮(有关物质G)、5-氯-N^(2)-[4-[1-[5-氯-4-[[2-(异丙基磺酰基)苯基]胺基]嘧啶-2-基]哌啶-4-基]-2-异丙氧基-5-甲基苯基]-N^(4)-[2-(异丙基磺酰基)苯基]-2,4-嘧啶二胺(有关物质H),且经^(1)H NMR和MS结构确证。 Eight related substances of ceritinib(1)were prepared according to its structure and synthetic process,namely 5-chloro-2-isopropoxy-N-[2-(isopropylsulfonyl)phenyl]pyrimidin-4-amine(related substance A),5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-ol(related substance B),5-chloro-N^(2)-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N^(4)-[2-(isopropylsulfinyl)phenyl]pyrimidine-2,4-diamine(related substance C),5-chloro-N^(2)-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N^(4)-[2-(propylsulfonyl)phenyl]pyrimidine-2,4-diamine(related substance D),5-chloro-N^(4)-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N^(2)-[2-(isopropylsulfonyl)phenyl]-pyrimidine-2,4-diamine(related substance E),2-[[5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]amino]-4-methyl-5-(piperidin-4-yl)phenol(related substance F),4-[4-[4-[[5-chloro-4-[[2-(isopropylsulfonyl)-phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidin-1-yl]pentan-2-one(related substance G),5-chloro-N^(2)-[4-[1-[5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]piperidin-4-yl]-2-isopropoxy-5-methylphenyl]-N^(4)-[2-(isopropylsulfonyl)phenyl]pyrimidine-2,4-diamine(related substance H).And their structures were confirmed by^(1)H NMR and MS.
作者 李振 陈素洁 赵国权 LI Zhen;CHEN Sujie;ZHAO Guoquan(Nanjing Caremo Biomedical Co.,Ltd.,Nanjing 210046)
出处 《中国医药工业杂志》 EI CAS CSCD 2024年第2期227-234,共8页 Chinese Journal of Pharmaceuticals
关键词 塞瑞替尼 ALK抑制剂 有关物质 合成 ceritinib ALK inhibitor related substance synthesis
  • 相关文献

参考文献2

二级参考文献5

  • 1TIMES O. FDA approval for Zykadia for late-stage lung cancere EB/OL]. [2014 - 04 - 29]. http://www. fda. gov/NewsEventsiNewsroomiPressAnnouncementslucm395299. htm.
  • 2CHASE W C F,BAILEY L,QUATTRONE D. FDA approves Novartis drug Zykadia ? for late-stage lung cancer [EB/OL]. [2014 - 04 - 29]. httpv'zwww, fccc. edulinformation/news/ press-releasesl2014 - 04 - 29. FDA-Approves-Novartis-DrugZykadia. html.
  • 3MARSYLJE T H, PEl W ,CHEN B, et al. Synthesis, structureactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase ( ALK) inhibitor 5- chloro-N-2-(2-isopropoxy-5-methyl-4-( piperidin-4-yl) phenyl) -N-4-( 2-( isopropylsulfonyl) phenyl) pyrimidine-2, 4-diamine ( LDK378) currently in phase I and phase 2 clinical trials] J]. J Med Chern ,2013 ,56(14) :5675 -5690.
  • 4CHEN J ,nANG C, WANG S. LDK378: a promising anaplastic lymphoma kinase ( ALK) inhibitor [J]. J Med Chern, 2013,56(14) :5673 -5674.
  • 5葛丹丹,宫平.色瑞替尼[J].中国药物化学杂志,2014,24(5):420-420. 被引量:6

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部